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Moisturisers are cornerstones of the management 
of atopic dermatitis (AD). Recently published 
guidelines on the management of AD recommend 
that ‘while the choice of moisturiser depends on 
individual preference, it should be safe; effective; 
cost-effective; and be fragrance/perfumes/additives-free’.[1] In spite of 
these recommendations, there has been an explosion of prescription 
and expensive moisturisers that contain various ingredients aimed 
at addressing the impaired skin barrier function in AD. These 
agents include prescription emollient devices and those containing 
ceramides and/or filaggrin breakdown products.[2-6] Such products 
increase the options for treating AD, but are expensive. There is also 
evidence that prescription moisturisers may not be superior to over-
the counter-preparations.[7]
The prevalence of AD is increasing worldwide.[8] In Cape Town, 
South Africa (SA), the 1-year prevalence in 13 - 14-year-old children 
was 8.3%, increasing to 13.3% in a later study.[9] Intractable pruritus 
and sleep disturbance can be severe in AD, compromising quality of 
life. Consistent with international practice, potential topical irritants 
(e.g. from ingredients responsible for fragrance, colour and foam) 
should be avoided. In keeping with the SA Essential Drugs List (EDL), 
the most commonly used products in public health facilities are 
aqueous cream as a soap substitute, with emulsifying ointment and 
cetomacrogol as moisturisers. Recently reported impairment of the 
skin barrier function in healthy subjects resulting from the use of aqueous 
cream as a daily moisturiser has raised concern.[10] AD is the leading 
single contributor to the ‘top ten paediatric dermatology diagnoses’, 
which account for >70% of patients in 12 of 19 international 
studies. [11] Up to 60% of patients attending the Dermatology Clinic at 
Red Cross War Memorial Children’s Hospital, Cape Town, SA, have 
AD, and often return with disease flares.[11] Many of these patients use 
only clinic-supplied EDL moisturisers, which are not stocked by rural 
shops, presumably because of cost. We found no data comparing 
commonly used AD emollients with products that are routinely 
used and available in most homes (petroleum jelly, glycerine and 
baby oil). Petroleum jelly and liquid paraffin combined in a 50:50 
formulation has been used locally and in the UK for AD.[12-14] 
We prefer the term ‘fragrance-free baby oil’ to ‘liquid paraffin’ in 
order to eliminate confusion with paraffin (kerosene) that is used 
as fuel (for cooking/heating). Baby oil is widely used all over the 
world on children, including neonates. Fragrance-free baby oil is 
also used as a bath additive in AD and locally as a soap substitute 
for patients who are unable to tolerate aqueous cream. Glycerine 
(glycerol) is a good humectant;[15,16] a deterrent to its use is its sticky 
consistency, which we have found disappears completely when it is 
combined with petroleum jelly. Mixing with glycerine also reduces 
the shine of petroleum jelly. A proportion of glycerine/petroleum 
in 1:2 formulation for use as a hand cream was preferred to other 
unlabelled proportions by 45 of 50 hospital staff (‘the 1:2 moisturiser’; 
unpublished data, N P Khumalo, 2012).
Objective
To compare the efficacy of easily accessible moisturisers with those 
currently recommended in patients with mild to moderate AD.
Methods
Study design and treatment groups
Approval to conduct the study was received from the Ethics 
Committee, Faculty of Health Sciences, University of Cape Town 
(ref: 146/2013). The trial was registered (NCT0208447). Two separate 
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substudies were conducted using a randomised controlled single 
(assessor)-blind trial design. Patients were randomised using an 
automatic online enrolment system in a 1:1 ratio for study 1 or a 
1:1:1:1 ratio for study 2.
Study 1 compared aqueous cream v. baby oil as a soap substitute. 
All the participants used emulsifying ointment as a moisturiser. 
Study 2 compared four moisturiser formulations: cetomacrogrol, 
emulsifying ointment, glycerine/petroleum (1:2) and petroleum 
jelly. Study 2 participants all washed with baby oil and applied this 
as soap instead of aqueous cream. All the participants continued to 
use clinic-prescribed topical steroids during the study period, and 
brought back all tubes so that the amount used during the previous 
month could be recorded at every visit.
Patients
Patients aged 1 - 12 years were enrolled at Red Cross Children’s 
War Memorial Hospital from 1 February 2013 to 31 June 2013. 
Written consent was signed by parents/guardians. All had active 
but stable mild to moderate atopic eczema according to the UK 
working party formulary criteria at screening and at baseline,[17] 
and all had dry eczematous skin as the predominant feature. 
Patients were not eligible if they had severe atopic eczema or 
secondary infection, were medically unwell, or were on systemic 
therapy for their AD.
Assessments
Visits occurred at baseline and monthly for 3 months, and the 
outcomes of interest were recorded. At each of the four visits, 
one ‘blinded’ dermatologist, who was the same for all visits, did 
all assessments. Disease severity was asessed using the validated 
objective SCORing Atopic Dermatitis (SCORAD), the Nottingham 
Atopic Eczema Severity Score (NESS) and the Patient Oriented 
Eczema Measure (POEM) scores. A validated quality-of-life form 
using the infant’s dermatitis quality of life (IDQOL) scale was 
completed by caregivers at each visit. The amount of topical steroids 
used in the preceding month was documented at each visit (i.e. 
number of tubes and proportion of partially used tubes). All 
caregivers were also requested to return all medication (received from 
any/all health facilities attended during the previous month). Adverse 
events were asked about and recorded at each visit.
Statistical analysis
Data were analysed using STATA version 13.1.[18] With an estimate 
of proportions of 33% v. 5% and a non-inferiority margin of 5%, the 
total sample size was 40 (20 per group for study 1). In the parallel-
design study, with the same parameters as above with adjustment for 
multiple testing, the total sample size was 44 × 2 = 88 (22 per group 
for study 2).  We compared SCORAD/NESS/POEM and IDQOL 
mean scores at baseline and weeks 4, 8 and 12 and summarised the 
findings by treatment group and time with interaction plots produced 
using R Version 3.0.2.[19] We used repeated-measures analysis of 
variance which utilised all data and assessed the effect of treatment 
and  time effect (interaction between time and treatment) using 
generalised estimating equations. The level of significance was set 
at p<0.05.
Results
A total of 125 children were screened and 120 randomised to provide 
20 in each treatment group in the two studies (Fig. 1) (it was only 
noticed towards the end of the study that 20 instead of 22 participants 
per group had been recruited for study 2). All baseline characteristics 
were similar between the groups except for the objective SCORAD 
in study 1, aqueous cream v. baby oil (mean (standard deviation, 
SD) 23.02 (11.79) v. 33.11 (16.82); p=0.042) (Table 1). One hundred 
and ten children completed the trial. Ten children (8.3%) dropped 
out, four having complained (noted at a visit before dropping out) 
of itching, presumed to be from baby oil (one in study 1 and three 
in study 2 – one from each group except the emulsifying ointment 
group). All participants in the aqueous cream and emulsifying 
ointment group completed the study. The reason for dropping out 
of the trial was unknown in six patients (two from study 1 and four 
from study 2 – two from the cetomacrogol group and two from 
the petroleum jelly group) (Fig.1). Overall there was no statistical 
difference in the number of dropouts between groups.
Table 1. Baseline characteristics of study participants*
Study 1 Baby oil Aqueous cream p-value
Age (years), mean (SD) 5.63 (2.43) 5.66 (2.39) 0.966
Females, n (%) 8/20 (40.0) 9/17 (52.9%) 0.431
Baseline scores (mean (SD)
SCORAD 23.02 (11.79) 33.11 (16.82) 0.042
POEM 9.00 (5.06) 11.50 (7.97) 0.366
NESS 10.20 (1.96) 9.50 (3.25) 0.429
IDQOL 6.45 (4.78) 7.00 (4.86) 0.736
Study 2
Emulsifying 
ointment Cetomacrogol Glycerine/petroleum jelly Petroleum jelly p-value
Age (years), mean (SD) 5.83 (2.61) 4.71 (2.86) 5.55 (2.58) 4.95 (2.45) 0.549
Females, n (%) 20 (55) 17 (41) 19 (58) 17 (53) 0.767
Baseline scores, mean (SD)
SCORAD 28.40 (16.16) 24.78 (16.90) 21.52 (15.24) 26.77 (12.09) 0.529
POEM 9.10 (4.56) 9.47 (6.02) 9.75 (7.23) 11.29 (7.06) 0.742
NESS 9.85 (2.83) 9.35 (2.40) 9.25 (3.64) 10.00 (3.35) 0.856
IDQOL 7.25 (5.84) 7.23 ( 4.48) 7.35 (6.75) 6.76 (3.72) 0.989
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All mean scores decreased over time. In study 
1, scores were similar except for the objective 
SCORAD, both at baseline and at the end of 
the study (p=0.022) (Fig. 2). In study 2, all 
mean scores tended to decline over time, but 
there were no differences in all treatments 
compared with emulsifying ointment 
(p=0.529) (Fig. 3). Furthermore, the IDQOL 
index did not change significantly from 
baseline in either study (p=0.736 for study 
1 and p=0.989 for study 2). There was no 
statistical difference in the amount of topical 
steroids (of various strengths) used between 
groups for either study (Fig. 3). Overall, 
there was no difference in adverse effects 
(itching) between groups (Fig. 1).
Discussion
Three separate disease severity scores were 
used in this trial to determine consistency 
of the results. It is interesting that overall 
there were no differences in severity 
scores between the groups from baseline 
and over time in any of the scores except 
SCORAD in study  1 (Fig. 2). However, 
this difference in the objective SCORAD 
was present both at baseline and over time 
and is therefore unlikely to be the result of 
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Fig. 1. Flow diagram depicting the overall study design.
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Fig. 2. Interaction plots of treatment by time (aqueous cream v. baby oil) in study 1. The y-axes show 
means at each time point. All the scores tend to decline over time for all the treatments. There is a 
significant difference between the treatments for objective SCORAD only (p=0.022), but this difference 
was also present at baseline (p=0.042) and is unlikely to be the result of treatment.
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different treatments. It is noteworthy that 
the amount (and potency) of steroids used 
did not differ between groups. Scores tended 
to decline over time from baseline for all the 
four treatment groups in study 2, suggesting 
that the moisturisers may be equivalent. 
Consistent with this finding is the IDQOL, 
which did not differ between groups in the 
two studies.
Fragrance-free baby oil baths, glycerine/
petroleum (the ‘1:2 moisturiser’) and petro-
leum jelly were generally well tolerated in 
both studies, with only four of 100 users (one 
in each of four study groups) complaining of 
itching, which was presumed to be associated 
with baby oil (applied directly to the skin as 
a soap substitute). Fragrance-free baby oil is 
commonly used and well tolerated as a bath 
additive by patients in our unit. Although 
there was no statistical difference in the 
prevalence of side-effects between groups, the 
few cases of irritation with baby oil were also 
unexpected because it is so commonly used 
worldwide in healthy neonates and children 
as well as as a moisturiser in the formulation 
liquid paraffin/petroleum jelly 50:50 in AD. 
Liquid paraffin-based emollients may contain 
1% sodium lauryl sulphate, which may irritate 
the skin. It was interesting that no participant 
complained of the shine of petroleum jelly, 
and that no case of (expected) occlusive 
folliculitis was noted. However, the petroleum 
jelly group did have a larger number of drop-
outs, although not significantly so, than the 
glycerine/petroleum group. A recent study 
has demonstrated impairment of the skin 
barrier function in healthy subjects using 
aqueous cream as a daily moisturiser; this 
is also thought to be the result of sodium 
lauryl sulphate in aqueous cream.[10] In our 
unit aqueous cream is not recommended as 
a moisturiser, a subset of patients finding it 
irritating even as a soap substitute. For these 
patients, emulsifying ointment or fragrance-
free baby oil have been acceptable soap 
substitutes.
Moisturisers are important as maintenance 
treatment and for prevention of flares in AD. 
Several clinical trials have shown that moisturis-
ers can lessen the symptoms and signs of AD 
and enhance the effects of, as well as reduce 
the amount of, topical corticosteroids needed 
for disease control.[1,20-21] Recently published 
studies tend to focus on new agents without 
comparing them with available treatments for 
AD. Despite a myriad of moisturiser choices 
in the literature, uncertainty as to which one to 
choose remains.
Patients with AD constitute the largest 
single diagnosis in paediatric dermatology 
clinics (including SA 59%, London 36%, 
Greece 35% and Hong Kong 33%) in 19 
studies from 16 countries.[11] Families of 
AD sufferers in poor settings become 
increasingly dependent on public health 
services, increasing pressure on public 
healthcare facilities. Although cetomacrogol 
and emulsifying ointment are considered 
inexpensive in Western countries, they are 
not affordable for most of our patients, who 
have easy access to but do not use petroleum 
jelly and baby oil, depending instead on 
government clinic suppliers. Even in well-
resourced countries, spiralling medical costs 
have increased the demand for evidence-
based cost-effective treatments. Results from 
this prospective controlled study revealed 
that more affordable moisturisers are 
effective alternatives for AD.
Study limitations
The small sample size is a limitation to this 
study, although calculations were adequately 
powered to detect differences in groups (at 
20 and 22 participants per group in studies 
1 and 2, respectively). However, it was only 
noticed towards the end of the study that 20 
instead of 22 participants per group had also 
(erroneously) been recruited for study 2. Loss 
to follow-up was minimal, with retention of 
92% of participants to the end of the study 
at 12 weeks – a longer duration of follow-up 
than in most AD moisturiser studies.[20,22-24]
Conclusion
This study suggests that affordable mois-
turisers are effective in the management of 
AD. The small sample size and single-centre 
setting limit generalisability. Fragrance-free 
baby oil is an alternative soap substitute, but 
may be better tolerated as a bath additive. 
Glycerine/petroleum (the ‘1:2 moisturiser’) 
may be preferred to petroleum jelly, but 
both are equivalent to standard moisturisers 
(cetomacrogol and emulsifying ointment) in 
mild to moderate AD. Use of accessible and 
affordable moisturisers could help empower 
families to better manage and reduce the cost 
of treating AD.
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